GC@ICG nanoparticle |
|
Vaxjo ID |
279 |
|
Vaccine Adjuvant Name |
GC@ICG nanoparticle |
|
Alternative Names |
Glycated chitosan with indocyanine green |
|
Adjuvant VO ID |
VO_0005607
|
|
Description |
A self-assembled nanoparticle composed of amphiphilic glycated chitosan (GC) and indocyanine green (ICG), used for photo-immunotherapy in triple-negative breast cancer (TNBC). Acts as a “Trojan Horse” for tumor cell uptake and immune activation |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Herein, we employed glycated chitosan (GC), a polysaccharide macromolecular immunoadjuvant, to construct a self-assembly GC@ICG nanoparticle which is accessible to tumor cells for synergistic cancer treatment based on the combination of phototherapy and immunotherapy. |
|
Structure |
Nanoparticles (~208 nm), spherical, amphiphilic polymer with 5β-cholanic acid-modified GC encapsulating ICG |
|
Appearance |
Spherical particles; good dispersion and uniformity under SEM |
|
Storage |
Stored in deionized water; stable for at least 10 days across pH 5.5–7.4 |
|
Preparation |
Synthesized via EDC/NHS-mediated coupling of 5β-cholanic acid to GC, followed by sonication with ICG and purification via centrifugation and dialysis |
|
Dosage |
ICG: 20 µg/mL; GC: 1% in 100 µL i.v. injection; treated tumors irradiated with 808 nm laser at 0.8 W/cm² for 10 min |
|
Function |
effective treatment methods are urgently needed to control primary tumors and suppress distant tumors. Herein, we employed glycated chitosan (GC), a polysaccharide macromolecular immunoadjuvant, to construct a self-assembly GC@ICG nanoparticle which is accessible to tumor cells for synergistic cancer treatment based on the combination of phototherapy and immunotherapy |
|
Safety |
Well-tolerated, no death or weight loss observed; no systemic toxicity within 7 days post-treatment |
| References |
Wu et al., 2022: Wu J, Wang S, Liu S, Liu F, Zhou F. Immunoadjuvant Nanoparticles as Trojan Horses for Enhanced Photo-Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Frontiers in pharmacology. 2022; 13; 883428. [PubMed: 35600886].
|
